Colorectal cancer
Colorectal cancer
复制标题
DOI：
10.1016/s0140-6736(98)07127-x
复制
发表时间：
1999-01-30
期刊：
影响因子：
168.9
通讯作者：
Kerr, D
中科院分区：
文献类型：
--
作者：
Midgley, R;Kerr, D
结直肠癌是发病率和死亡率的主要原因，在欧洲和美国每年约有30万新发病例和20万例死亡。（1，2）已发表的试验已经确定了化疗在结直肠癌中的作用，在Dukes C结肠癌的辅助治疗中，绝对生存获益约为5%，在晚期结直肠癌中，它改善了生活质量，延长了6- 1,2个月的生存期。对于直肠癌，放射治疗可降低局部复发率，对于局部晚期疾病，可成功缓解疼痛、里急后重和出血。对结直肠癌发生的不断发展的理解，特别是对在肿瘤发展过程中可能发生突变或丢失的重要基因的认识，已被转化为创新的基因治疗技术。最后，越来越明显的是，手术部位专业化和多学科方法（包括外科医生，病理学家和肿瘤学家）可能会为结直肠癌患者带来最佳结果。
Colorectal cancer is a leading cause of morbidity and mortality with about 300000 new cases and 200000 deaths in Europe and the USA each year.(1,2) published trials have established a role for chemotherapy in colorectal cancer, in the adjuvant setting for Dukes C colon cancer, with an absolute survival benefit of about 5% and in advanced colorectal cancer, for which it improves quality of life and increases survival by 6-12 months. For rectal cancer, radiotherapy decreases rates of local recurrence and, in locally advanced disease, successfully palliates pain, tenesmus, and bleeding. The evolving understanding of colorectal carcinogenesis, in particular recognition of vital genes that may be mutated or lost during tumour development, has been translated into innovative gene therapy techniques. Finally it is increasingly apparent that surgical site specialisation and a multidisciplinary approach (including surgeons, pathologists, and oncologists) may lead to optimum outcomes for patients with colorectal cancer.